- Home
- Companies
- Hanson Wade Group
- Events
- 16th World Clinical Biomarkers & ...
16th World Clinical Biomarkers & Companion Diagnostics Summit Europe - 2026
Validating Complex Biomarker Panels & Innovative Diagnostic Platforms Across Europe For Scalable Precision Medicine Approvals, Adoption & Market Access. With IVDR performance study guidance now in force, German reimbursement reforms underway, and NHS England advancing liquid biopsy rollouts, Europe is entering a new era of precision medicine. As novel and digital diagnostics accelerate, the question is no longer whether they enable fit-for-purpose biomarker strategies, but how quickly clinical, regulatory, and commercial systems can keep pace. Amid this momentum, the 16th World Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the region’s longest-standing precision medicine forum, bringing together 300+ senior leaders across biopharma, diagnostics, regulation, reimbursement, and healthcare to define biomarker strategies and ensure day-one drug-diagnostic market readiness.
Featuring brand-new case studies from 60+ expert speakers, this meeting is the definitive European platform for knowledge exchange and collaboration, removing barriers to faster, more equitable precision healthcare across oncology, neurological, autoimmune, and chronic diseases.
Europe accelerates its precision medicine ecosystem propelled by IVDR implementation, expanding molecular testing capacity, and coordinated early detection initiatives, the 16th World Clinical Biomarkers & Companion Diagnostics showcases the region’s latest advances in biomarker-guided trials, CDx regulation, and cross-border drug-diagnostic co-development to accelerate access to targeted therapies across oncology and beyond. Uniting leading decision makers from biopharma, diagnostic developers, regulatory bodies, healthcare institutions, and testing laboratories, this summit empowers scalable, timely, and equitable diagnostic adoption for diverse patient populations across Europe.
Europe’s precision medicine landscape is rapidly evolving, with biomarker strategies for next-generation therapies, the COMBINE pilot in action, and early detection initiatives scaling. To this end, Biopharma companies are forging strategic partnerships with diagnostics developers, testing laboratories, and regulatory experts to shape the future of drug-diagnostic co-development across oncology, neurological, rare, chronic, and other complex diseases.
Now in its sixteenth year, the 16th Clinical Biomarkers & Companion Diagnostics Summit Europe returns as the region’s most established meeting shaping biomarker strategy and day-one CDx readiness. Offering a critical window to establish or scale your presence in a market defined by fast-paced innovation, evolving regulation, and growing demand for localized and scalable diagnostic solutions.
Trusted by leading global drug developers and diagnostic innovators alike, this is where pivotal partnerships are formed, and next generation companion diagnostic and liquid biopsy platforms are accelerated for European market access.
Expand your European network with face-to-face engagement among senior precision medicine leaders from EU and UK biopharma, diagnostics developers, CROs, testing laboratories, and regulatory agencies, actively seeking innovative partners to accelerate biomarker discovery, CDx development, and IVDR-compliant clinical execution.
Strengthen your brand presence among senior industry decision-makers by showcasing your company logo on event materials including our website, brochure, and on-site signage.
Present your services on centre stage, participate in a panel discussion or showcase your solutions in a bespoke exhibition booth to demonstrate your company as a trusted partner in advancing precision diagnostics and personalized therapy development across Europe.
Stay ahead of rapidly evolving European market trends by hearing directly from industry pioneers and regulatory authorities. Understand competitor strategies, upcoming IVDR milestones, payer expectations, and emerging diagnostic models to refine your organization’s roadmap and sharpen your competitive edge.
Our industry attendees are looking for service and solution providers with capabilities in the below areas but not limited to:
- Advancing compliant companion diagnostics solutions from bench to bedside
- Improving early detection, patient selection and monitoring with liquid biopsy platforms
- Identifying clinically meaningful biomarkers with novel IVD assay spanning imaging, functional assays, genetics, omics and multi-modal models
- Enhancing data-driven strategies with AI-enabled translational tools and in vitro diagnostics
- Bolstering accessible and scalable diagnostic testing across Europe through centralized and decentralized clinical laboratories
- Accelerating towards harmonized Rx-Dx approvals, with strong IVDR experience and local medicines agency compliance
- Integrating RWE with clinical trial results to inform iterative biomarker validation, label expansion, and adaptive trial design
- Refining biomarker operations and pre-analytical workflows to ensure high-quality, reproducible biomarker data and workstreams